

S. 2985

A. 4579

2011-2012 Regular Sessions

S E N A T E - A S S E M B L Y

February 4, 2011

---

IN SENATE -- Introduced by Sens. LAVALLE, DeFRANCISCO, FUSCHILLO, GRIFO, LARKIN, LITTLE, RANZENHOFER -- read twice and ordered printed, and when printed to be committed to the Committee on Higher Education

IN ASSEMBLY -- Introduced by M. of A. CANESTRARI, GOTTFRIED, COLTON, ENGLEBRIGHT, PAULIN, BURLING, LIFTON, ORTIZ, BROOK-KRASNY, GABRYSZAK, SCHROEDER, MAYERSOHN, CASTELLI, SPANO, GUNTHER, SCHIMEL, JAFFEE, WEISENBERG, HOYT -- Multi-Sponsored by -- M. of A. AMEDORE, BENEDETTO, BOYLAND, BRENNAN, BUTLER, CONTE, CROUCH, CYMBROWITZ, DESTITO, GALEF, GANTT, HAWLEY, HEVESI, JACOBS, LATIMER, LAVINE, V. LOPEZ, LUPARDO, MAGEE, MARKEY, McDONOUGH, McENENY, J. MILLER, MORELLE, PEOPLES-STOKES, PHEFFER, PRETLOW, RAIA, REILLY, ROSENTHAL, SAYWARD, THIELE, WRIGHT -- read once and referred to the Committee on Higher Education

AN ACT to amend the education law, in relation to authorizing pharmacists to perform collaborative drug therapy management with physicians in certain settings and providing for the repeal of such provisions upon expiration thereof

THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEMBLY, DO ENACT AS FOLLOWS:

1     Section 1. Subdivision 1 of section 6801 of the education law, as  
2     amended by chapter 563 of the laws of 2008, is amended to read as  
3     follows:  
4     1. The practice of the profession of pharmacy is defined as the admin-  
5     istering, preparing, compounding, preserving, or the dispensing of  
6     drugs, medicines and therapeutic devices on the basis of prescriptions  
7     or other legal authority, AND COLLABORATIVE DRUG THERAPY MANAGEMENT IN  
8     ACCORDANCE WITH THE PROVISIONS OF SECTION SIXTY-EIGHT HUNDRED ONE-A OF  
9     THIS ARTICLE.  
10    S 1-a. Section 6801 of the education law, as added by chapter 987 of  
11    the laws of 1971, is amended to read as follows:  
12    S 6801. Definition of practice of pharmacy.     The practice of the  
13    profession of pharmacy is defined as the preparing, compounding,  
14    preserving, or the dispensing of drugs, medicines and therapeutic  
15    devices on the basis of prescriptions or other legal authority, AND

EXPLANATION--Matter in *ITALICS* (underscored) is new; matter in brackets  
[ ] is old law to be omitted.

LBD06072-01-1

1 COLLABORATIVE DRUG THERAPY MANAGEMENT IN ACCORDANCE WITH THE PROVISIONS  
2 OF SECTION SIXTY-EIGHT HUNDRED ONE-A OF THIS ARTICLE.

3 S 2. The education law is amended by adding a new section 6801-a to  
4 read as follows:

5 S 6801-A. COLLABORATIVE DRUG THERAPY MANAGEMENT DEMONSTRATION PROGRAM.

6 1. AS USED IN THIS SECTION, THE FOLLOWING TERMS SHALL HAVE THE FOLLOW-  
7 ING MEANINGS:

8 A. "COLLABORATIVE DRUG THERAPY MANAGEMENT" SHALL MEAN THE PERFORMANCE  
9 OF SERVICES BY A PHARMACIST RELATING TO THE REVIEW, EVALUATION AND  
10 MANAGEMENT OF DRUG THERAPY TO A PATIENT, WHO IS BEING TREATED BY A  
11 PHYSICIAN FOR A SPECIFIC DISEASE OR DISEASE STATE, IN ACCORDANCE WITH A  
12 WRITTEN AGREEMENT OR PROTOCOL WITH A VOLUNTARILY PARTICIPATING PHYSICIAN  
13 AND IN ACCORDANCE WITH THE POLICIES, PROCEDURES, AND PROTOCOLS OF THE  
14 FACILITY. SUCH AGREEMENT OR PROTOCOL AS ENTERED INTO BY THE PHYSICIAN  
15 AND A PHARMACIST, MAY INCLUDE, AND SHALL BE LIMITED TO:

16 (I) ADJUSTING OR MANAGING A DRUG REGIMEN OF A PATIENT, PURSUANT TO A  
17 PATIENT SPECIFIC WRITTEN ORDER OR PROTOCOL MADE BY THE PATIENT'S PHYSI-  
18 CIAN, WHICH MAY INCLUDE ADJUSTING DRUG STRENGTH, FREQUENCY OF ADMINIS-  
19 TRATION OR ROUTE OF ADMINISTRATION. ADJUSTING THE DRUG REGIMEN SHALL NOT  
20 INCLUDE SUBSTITUTING OR SELECTING A DIFFERENT DRUG WHICH DIFFERS FROM  
21 THAT INITIALLY PRESCRIBED BY THE PATIENT'S PHYSICIAN UNLESS SUCH SUBSTI-  
22 TUTION IS EXPRESSLY AUTHORIZED IN THE WRITTEN ORDER OR PROTOCOL. THE  
23 PHARMACIST SHALL BE REQUIRED TO IMMEDIATELY ENTER INTO THE PATIENT  
24 RECORD ANY CHANGE OR CHANGES MADE TO THE PATIENT'S DRUG THERAPY AND  
25 SHALL USE ANY REASONABLE MEANS OR METHOD ESTABLISHED BY THE FACILITY OR  
26 THE DEPARTMENT TO NOTIFY ANY OF THE PATIENT'S OTHER TREATING PHYSICIANS  
27 WITH WHOM HE OR SHE DOES NOT HAVE A WRITTEN AGREEMENT OR PROTOCOL  
28 REGARDING SUCH CHANGES. THE PATIENT'S PHYSICIAN MAY PROHIBIT, BY WRITTEN  
29 INSTRUCTION, ANY ADJUSTMENT OR CHANGE IN THE PATIENT'S DRUG REGIMEN BY  
30 THE PHARMACIST;

31 (II) EVALUATING AND, ONLY IF SPECIFICALLY AUTHORIZED BY THE PROTOCOL  
32 AND ONLY TO THE EXTENT NECESSARY TO DISCHARGE THE RESPONSIBILITIES SET  
33 FORTH IN THIS SECTION, ORDERING CLINICAL LABORATORY TESTS RELATED TO THE  
34 DRUG THERAPY MANAGEMENT FOR THE SPECIFIC DISEASE OR DISEASE STATE SPECI-  
35 FIED WITHIN THE PROTOCOL; AND

36 (III) ONLY IF SPECIFICALLY AUTHORIZED BY THE PROTOCOL AND ONLY TO THE  
37 EXTENT NECESSARY TO DISCHARGE THE RESPONSIBILITIES SET FORTH IN THIS  
38 SECTION, ORDERING OR PERFORMING ROUTINE PATIENT MONITORING FUNCTIONS AS  
39 MAY BE NECESSARY IN THE DRUG THERAPY MANAGEMENT, INCLUDING THE COLLECT-  
40 ING AND REVIEWING OF PATIENT HISTORIES, AND ORDERING OR CHECKING PATIENT  
41 VITAL SIGNS, INCLUDING PULSE, TEMPERATURE, BLOOD PRESSURE AND RESPIRA-  
42 TION.

43 B. "WRITTEN AGREEMENT OR PROTOCOL" SHALL MEAN A WRITTEN DOCUMENT,  
44 PURSUANT TO AND CONSISTENT WITH ANY APPLICABLE STATE OR FEDERAL REQUIRE-  
45 MENTS, THAT ADDRESSES A SPECIFIC DISEASE OR DISEASE STATE AND THAT  
46 DESCRIBES THE NATURE AND SCOPE OF COLLABORATIVE DRUG THERAPY MANAGEMENT  
47 TO BE UNDERTAKEN BY THE PHARMACIST, IN COLLABORATION WITH THE PARTIC-  
48 IPATING PHYSICIAN, IN ACCORDANCE WITH THE PROVISIONS OF THIS SECTION.

49 C. "PHYSICIAN" SHALL MEAN THE PHYSICIAN, SELECTED BY OR ASSIGNED TO A  
50 PATIENT, WHO HAS PRIMARY RESPONSIBILITY FOR THE TREATMENT AND CARE OF  
51 THE PATIENT FOR THE DISEASE OR DISEASE STATE THAT IS THE SUBJECT OF THE  
52 COLLABORATIVE DRUG THERAPY MANAGEMENT.

53 D. "FACILITY" SHALL MEAN A TEACHING HOSPITAL, INCLUDING ANY DIAGNOSTIC  
54 CENTER, TREATMENT CENTER, OR HOSPITAL-BASED OUTPATIENT DEPARTMENT,  
55 HOWEVER, FOR THE PURPOSES OF THIS SECTION, RESIDENTIAL HEALTH CARE  
56 FACILITIES AND NURSING HOMES SHALL BE EXCLUDED. FOR THE PURPOSES OF THIS

SECTION, A "TEACHING HOSPITAL" SHALL MEAN A HOSPITAL LICENSED PURSUANT TO ARTICLE TWENTY-EIGHT OF THE PUBLIC HEALTH LAW THAT IS ELIGIBLE TO RECEIVE DIRECT OR INDIRECT GRADUATE MEDICAL EDUCATION PAYMENTS PURSUANT TO ARTICLE TWENTY-EIGHT OF THE PUBLIC HEALTH LAW.

2. A. A PHARMACIST WHO MEETS THE EXPERIENCE REQUIREMENTS OF PARAGRAPH B OF THIS SUBDIVISION AND WHO IS EMPLOYED BY OR OTHERWISE AFFILIATED WITH A FACILITY SHALL BE PERMITTED TO ENTER INTO A WRITTEN AGREEMENT OR PROTOCOL WITH A PHYSICIAN AUTHORIZING COLLABORATIVE DRUG THERAPY MANAGEMENT, SUBJECT TO THE LIMITATIONS SET FORTH IN THIS SECTION, WITHIN THE SCOPE OF SUCH EMPLOYMENT OR AFFILIATION.

B. A PARTICIPATING PHARMACIST MUST:

(I)(A) HAVE BEEN AWARDED EITHER A MASTER OF SCIENCE IN CLINICAL PHARMACY OR A DOCTOR OF PHARMACY DEGREE;

(B) MAINTAIN A CURRENT UNRESTRICTED LICENSE; AND

(C) HAVE A MINIMUM OF TWO YEARS EXPERIENCE, OF WHICH AT LEAST ONE YEAR OF SUCH EXPERIENCE SHALL INCLUDE CLINICAL EXPERIENCE IN A HEALTH FACILITY, WHICH INVOLVES CONSULTATION WITH PHYSICIANS WITH RESPECT TO DRUG THERAPY AND MAY INCLUDE A RESIDENCY AT A FACILITY INVOLVING SUCH CONSULTATION; OR

(II)(A) HAVE BEEN AWARDED A BACHELOR OF SCIENCE IN PHARMACY;

(B) MAINTAIN A CURRENT UNRESTRICTED LICENSE; AND

(C) WITHIN THE LAST SEVEN YEARS, HAVE A MINIMUM OF THREE YEARS EXPERIENCE, OF WHICH AT LEAST ONE YEAR OF SUCH EXPERIENCE SHALL INCLUDE CLINICAL EXPERIENCE IN A HEALTH FACILITY, WHICH INVOLVES CONSULTATION WITH PHYSICIANS WITH RESPECT TO DRUG THERAPY AND MAY INCLUDE A RESIDENCY AT A FACILITY INVOLVING SUCH CONSULTATION.

C. NOTWITHSTANDING ANY PROVISION OF THIS SECTION, NOTHING HEREIN SHALL AUTHORIZE THE PHARMACIST TO DIAGNOSE DISEASE. IN THE EVENT THAT A TREATING PHYSICIAN MAY DISAGREE WITH THE EXERCISE OF PROFESSIONAL JUDGMENT BY THE PHARMACIST, THE JUDGMENT OF THE TREATING PHYSICIAN SHALL PREVAIL.

3. THE PHYSICIAN WHO IS A PARTY TO A WRITTEN AGREEMENT OR PROTOCOL AUTHORIZING COLLABORATIVE DRUG THERAPY MANAGEMENT SHALL BE EMPLOYED BY OR OTHERWISE AFFILIATED WITH THE SAME FACILITY WITH WHICH THE PHARMACIST IS ALSO EMPLOYED OR AFFILIATED.

4. THE EXISTENCE OF A WRITTEN AGREEMENT OR PROTOCOL ON COLLABORATIVE DRUG THERAPY MANAGEMENT AND THE PATIENT'S RIGHT TO CHOOSE TO NOT PARTICIPATE IN COLLABORATIVE DRUG THERAPY MANAGEMENT SHALL BE DISCLOSED TO ANY PATIENT WHO IS ELIGIBLE TO RECEIVE COLLABORATIVE DRUG THERAPY MANAGEMENT. COLLABORATIVE DRUG THERAPY MANAGEMENT SHALL NOT BE UTILIZED UNLESS THE PATIENT OR THE PATIENT'S AUTHORIZED REPRESENTATIVE CONSENTS, IN WRITING, TO SUCH MANAGEMENT. IF THE PATIENT OR THE PATIENT'S AUTHORIZED REPRESENTATIVE CONSENTS, IT SHALL BE NOTED ON THE PATIENT'S MEDICAL RECORD. IF THE PATIENT OR THE PATIENT'S AUTHORIZED REPRESENTATIVE WHO CONSENTED TO COLLABORATIVE DRUG THERAPY MANAGEMENT CHOOSES TO NO LONGER PARTICIPATE IN SUCH MANAGEMENT, AT ANY TIME, IT SHALL BE NOTED ON THE PATIENT'S MEDICAL RECORD. IN ADDITION, THE EXISTENCE OF THE WRITTEN AGREEMENT OR PROTOCOL AND THE PATIENT'S CONSENT TO SUCH MANAGEMENT SHALL BE DISCLOSED TO THE PATIENT'S PRIMARY PHYSICIAN AND ANY OTHER TREATING PHYSICIAN OR HEALTHCARE PROVIDER.

5. PARTICIPATION IN A WRITTEN AGREEMENT OR PROTOCOL AUTHORIZING COLLABORATIVE DRUG THERAPY MANAGEMENT SHALL BE VOLUNTARY, AND NO PATIENT, PHYSICIAN, PHARMACIST, OR FACILITY SHALL BE REQUIRED TO PARTICIPATE.

6. NOTHING IN THIS SECTION SHALL BE DEEMED TO LIMIT THE SCOPE OF PRACTICE OF PHARMACY NOR BE DEEMED TO LIMIT THE AUTHORITY OF PHARMACISTS AND

1 PHYSICIANS TO ENGAGE IN MEDICATION MANAGEMENT PRIOR TO THE EFFECTIVE  
2 DATE OF THIS SECTION AND TO THE EXTENT AUTHORIZED BY LAW.

3 S 3. Subdivision 2 of section 6827 of the education law, as added by  
4 chapter 311 of the laws of 1996, is amended to read as follows:

5 2. During each triennial registration period an applicant for regis-  
6 tration shall complete a minimum of forty-five hours of acceptable  
7 formal continuing education, as specified in subdivision four of this  
8 section, provided that no more than twenty-two hours of such continuing  
9 education shall consist of self-study courses. ANY PHARMACIST PARTIC-  
10 IPATING IN COLLABORATIVE DRUG THERAPY MANAGEMENT PURSUANT TO SECTION SIX  
11 THOUSAND EIGHT HUNDRED ONE-A OF THIS ARTICLE SHALL COMPLETE AT LEAST  
12 FIVE HOURS OF ACCEPTABLE FORMAL CONTINUING EDUCATION IN THE AREA OR  
13 AREAS OF PRACTICE GENERALLY RELATED TO ANY COLLABORATIVE DRUG THERAPY  
14 MANAGEMENT PROTOCOLS TO WHICH THE PHARMACIST MAY BE SUBJECT. Any phar-  
15 macist whose first registration date following the effective date of  
16 this section occurs less than three years from such effective date, but  
17 on or after January first, nineteen hundred ninety-eight, shall complete  
18 continuing education hours on a prorated basis at the rate of one and  
19 one-quarter hours per month for the period beginning January first,  
20 nineteen hundred ninety-seven up to the first registration date there-  
21 after. A licensee who has not satisfied the mandatory continuing educa-  
22 tion requirements shall not be issued a triennial registration certif-  
23 icate by the department and shall not practice unless and until a  
24 conditional registration certificate is issued as provided for in subdi-  
25 vision three of this section. Continuing education hours taken during  
26 one triennium may not be transferred to a subsequent triennium.

27 S 4. The department of education, in consultation with the department  
28 of health, shall prepare or shall arrange for the preparation of a  
29 report on the implementation of collaborative drug therapy management  
30 (CDTM) in New York state. The report shall be submitted to the speaker  
31 of the assembly and the temporary president of the senate and the chairs  
32 of the senate and assembly higher education committees at least four  
33 months prior to the expiration of this act. The report shall review the  
34 extent to which CDTM was implemented in New York state and shall examine  
35 whether and the extent to which CDTM contributed to the improvement of  
36 quality of care for patients, reduced the risk of medication error,  
37 reduced unnecessary health care expenditures, and was otherwise in the  
38 public interest. The report may make recommendations regarding the  
39 extension, alteration and/or expansion of these provisions and make any  
40 other recommendations related to the implementation of CDTM pursuant to  
41 this act.

42 S 5. This act shall take effect on the one hundred twentieth day after  
43 it shall have become a law and shall expire 3 years after such effective  
44 date when upon such date the provisions of this act shall be deemed  
45 repealed; provided, however, that the amendments to subdivision 1 of  
46 section 6801 of the education law made by section one of this act shall  
47 be subject to the expiration and reversion of such subdivision pursuant  
48 to section 8 of chapter 563 of the laws of 2008, when upon such date the  
49 provisions of section one-a of this act shall take effect; provided,  
50 further, that effective immediately, the addition, amendment and/or  
51 repeal of any rule or regulation necessary for the implementation of  
52 this act on its effective date is authorized and directed to be made and  
53 completed on or before such effective date.